ZHENG, Xiaoling,SHEN, Wang,ZHANG, Aimin,MAUNG, Jack
申请号：
AU2018267622
公开号：
AU2018267622A1
申请日:
2018.11.22
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
#$%^&*AU2018267622A120181213.pdf#####ABSTRACT The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer).
